title: Developing EZH2-Targeted Therapy for Lung Cancer.
abstract: Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.
authors: Department of Internal Medicine and Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
authors: Arthur E
authors: AE
authors: Frankel
authors: Cecil H. and Ida Green Center for Reproductive Biologic Sciences and Division of Basic Sciences, Department of Obstetrics and Gynecology and Department of Biophysics, The University of Texas Southwestern Medical Center, Dallas, Texas.
authors: Xin
authors: X
authors: Liu
authors: Department of Internal Medicine and Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas. Hamon Center for Therapeutic Oncology Research and Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas. john.minna@utsouthwestern.edu.
authors: John D
authors: JD
authors: Minna
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D055808:Drug Discovery; D000071221:Enhancer of Zeste Homolog 2 Protein / Q000037:antagonists & inhibitors*; D044127:Epigenesis, Genetic / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D058990:Molecular Targeted Therapy; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D000071221:Enhancer of Zeste Homolog 2 Protein